UK MRC (UK Medical Research Council) biobank and stem cells under scrutiny:
This article was originally published in Clinica
The UK Medical Research Council (MRC) is to stand before the House of Commons' Select Committee for Science and Technology (STC) on December 4 2002 to present evidence of its work and expenditure plans. Among the issues on the agenda are the Biobank and Stem Cell Bank projects (see Clinica No 1024, p 8). The Committee will consider comments on these and other areas of the MRC's work, by November 22. The meeting, which will be open to the public, is part of the ongoing programme of scrutiny of the UK's Research Councils, conducted under the STC's remit to examine the expenditure, policy and administration of the Office of Science and Technology and its associated public bodies.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife
Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.